Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
TVGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Tevogen Bio Holdings Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tevogen Bio Holdings Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How TVGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every TVGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TVGN 489 | COVID-19 and Long COVID | 2025-10-15 | The dose-finding clinical trial of TVGN 489 demonstrated a favorable safety profile, providing valuable insights for further development, although specific efficacy metrics or outcomes were not disclosed in the press release.Read More | Tevogen Updates on TVGN 489 Following Growing Long COVID Patient InterestRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sordillo Victor J.Director | Grant/Award | 40,000 51,539 held | $0.00 | 07/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TVGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TVGN for Q3 2026. | ||||
Ownership Trends
TVGN Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How TVGN ranks across every disease it competes in
TVGN News
Tevogen Highlights Significant Liability Reduction and Continued Insider Control
Tevogen Inc. reported a significant reduction in liabilities from $99.9 million in 2023 to $14.8 million as of September 30, 2026. Insider ownership rose to 92%, reflecting strong control by the management team. The company's loss from operations also decreased by 17%, indicating improved financial performance.
Read more →Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement
Tevogen Inc. has extended its loan agreement with The Patel Family, LLP to May 2029, increasing its borrowing capacity to $28.6 million. This extension complements the company's existing ATM equity program, which allows for up to $50 million in sales. CEO Ryan Saadi emphasized a disciplined approach to financing.
Read more →UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
Tevogen Inc. signed a non-binding letter of intent to evaluate acquiring HRK Healthcare LLC. The deal could expand its healthcare services arm and support a $100 million annual revenue target. CEO Ryan Saadi hopes to close the transaction by the end of the fourth quarter of 2026. The agreement remains subject to due diligence and customary closing conditions.
Read more →Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
Tevogen Inc. announced it has regained compliance with Nasdaq's listing requirements. The company met the $50 million minimum market value of listed securities requirement. This follows a previous notice confirming compliance with the minimum market value of publicly held shares. All related Nasdaq compliance matters are now resolved.
Read more →Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
Tevogen Bio Holdings Inc. will officially operate as Tevogen Inc. starting July 30, 2026, following Board approval. This name change signifies the company's transition into a healthcare enterprise focused on integrating biotechnology, artificial intelligence, and healthcare services. The firm aims to enhance the affordability and accessibility of life-saving medicines while continuing to trade under the ticker symbols TVGN and TVGNW.
Read more →Tevogen Bio Announces 2026 Annual Meeting of Stockholders
Tevogen Bio Holdings Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for August 24, 2026. Stockholders of record as of July 23, 2026, will be eligible to vote. Proposals for consideration must be submitted by the same date, adhering to SEC rules and the company's bylaws. Tevogen aims to enhance healthcare accessibility through its various initiatives.
Read more →Tevogen Announces Formation of a Healthcare Services Initiative
Tevogen Bio Holdings Inc. has announced the formation of a healthcare services initiative aimed at expanding its revenue-generating capabilities. Led by interim head William Keane, the initiative may involve acquiring a Management Services Organization and a Contract Research Organization, potentially generating $100 million in annual revenue. This move aligns with Tevogen's mission to enhance healthcare affordability and access.
Read more →Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
Tevogen Bio Holdings Inc. has announced progress in its strategic acquisition initiatives, potentially leading to approximately $100 million in combined annual revenue. The company aims to evolve into a financially self-sufficient healthcare enterprise by exploring acquisitions that complement its existing biotechnology and technology arms. While the initiatives present significant financial potential, they are dependent on due diligence and approvals, and their success is uncertain.
Read more →Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
Tevogen Bio Holdings Inc. has signed a Letter of Intent to explore a potential acquisition of a Management Services Organization. This move is aimed at enhancing its healthcare infrastructure and supports the company's evolution into a revenue-generating entity. The CEO expressed that, if successful, the transaction could contribute to an estimated $100 million in annual revenue. However, the completion of the deal is contingent on due diligence, negotiation, and approval processes, which presents inherent uncertainties.
Read more →Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen Bio Holdings Inc. has reported a significant reduction in operational losses, with a 51% decline from 2024 to 2025. The company is advancing its strategic initiatives, including the Tevogen.AI project and expanding its cell therapy pipeline. CEO Dr. Ryan Saadi emphasized the importance of aligning long-term incentives with performance milestones while maintaining a focus on shareholder equity.
Read more →Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
Tevogen Bio Holdings Inc. has announced a $3 million private investment with The Patel Family, LLP, priced at a 14% premium to its latest closing price. This investment aims to enhance Tevogen's operational capabilities, support growth initiatives, and solidify its financial foundation. The financing agreement involves the issuance of 375,000 prefunded warrants, which will close on May 13, 2026. Tevogen's management expressed optimism about the financing's potential benefits in achieving significant revenue milestones.
Read more →Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
Tevogen Bio Holdings Inc. has announced significant advancements in its AI initiative, Tevogen.AI, with the PredicTcell™ training algorithm nearing completion. The model has shown a 10% improvement in precision and the company is exploring partnerships to enhance its application. Additionally, an internal application portal has been developed to streamline workflows and support future commercial efforts.
Read more →Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Tevogen Bio Holdings Inc. is evaluating a contract research organization (CRO) to enhance its clinical research capabilities. This potential transaction could generate over $20 million in annual revenue and support double-digit growth. The CEO highlighted the company's ambition to achieve a cash flow positive model while expanding its focus on oncology and rare diseases.
Read more →Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tevogen Bio Holdings Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after facing non-compliance in September 2025. The company aims to transform into a comprehensive healthcare enterprise by combining immunotherapy and artificial intelligence while exploring new strategic initiatives. These initiatives focus on enhancing patient access and affordability while aiming for a cash-flow-positive model. Tevogen's pipeline spans several therapeutic areas, reflecting its commitment to sustainable innovation in healthcare.
Read more →Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Tevogen Bio Holdings Inc. announced that Mittul Mehta, the Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026) in March 2026. His sessions will focus on the intersection of data engineering and artificial intelligence, addressing modernizing data architecture and building adaptive data pipelines. These themes align with Tevogen.AI's efforts to utilize advanced machine learning to improve biomedical discovery and patient treatment solutions. This participation highlights Tevogen's commitment to integrating cutting-edge technology in healthcare.
Read more →Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
Tevogen has provided a strategic update emphasizing its commitment to capital discipline, including the decision to limit share utilization to no more than 1% of its authorized shares in the coming year. The lead investor has expressed strong confidence in Tevogen's growth potential and proprietary technology. Additionally, the company is evaluating acquisitions that could generate over $50 million in annual revenue and is considering a one-time special cash dividend based on future financial milestones. Tevogen's approach reflects a dedication to long-term value creation and operational efficiency.
Read more →Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
Tevogen Bio Holdings Inc. has reported advancements in its artificial intelligence platform, Tevogen.AI, specifically in the PredicTcell™ model. The company achieved significant improvements in prediction accuracy, with recall increasing to 92% and precision rising to 48%. Additionally, Tevogen.AI has expanded its proprietary database to over 655 million peptide sequences, enabling more robust model training and target identification. The company plans to explore partnerships to advance its peptide candidates as predictive accuracy continues to improve.
Read more →Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
Tevogen, led by CEO Dr. Ryan Saadi, has reiterated its commitment to clinical development during International Long COVID Awareness Month. The company is advancing its investigational T-cell therapy, TVGN 489, and evaluating the acquisition of the Sciometrix Clinicus platform for real-world monitoring of Long COVID patients. Recent proof-of-concept results show that all treated high-risk patients did not develop Long COVID. With plans to expand its HLA target coverage, Tevogen aims to enhance accessibility for a larger portion of the U.S. population.
Read more →Tevogen Names Leadership Team to Execute Diversified Growth Strategy
Tevogen Bio Holdings Inc. has appointed interim leaders across its core business sectors to implement a diversified growth strategy. This strategy aims to explore opportunities that could generate over $50 million in annual revenues, with expected closures by Q2 2026. The company is leveraging advanced technologies in healthcare, including AI and precision T cell therapies, to enhance its offerings.
Read more →